Vaxxel
The future of vaccines against respiratory infections.
Vaxxel develops novel and proprietary live-attenuated vaccines candidate against bronchiolitis and pneumonia and in particular against human Metnapneumovirus and against human Respiratory Virus. Vaxxel is a spin off fom Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), Pr. Guy Boivin of the University of Laval (Quebec), by Denis Cavert, President of Vaxxel.